Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis

Journal of Clinical Oncology

Volumn 30, Issue 12, 2012, Pages

  Álvarez Twose, Iván ^a   González, Pablo ^b   Morgado, José Mário ^a   Jara Acevedo, María ^c   Sánchez Muñoz, Laura ^a   Matito, Almudena ^a   Mollejo, Manuela ^a   Orfao, Alberto ^c   Escribano, Luis ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c Centro de Investigacion del Cancer   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DRUG DOSE INCREASE; FLOW CYTOMETRY; HUMAN; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SELF ESTEEM; SKIN BIOPSY; SOCIAL ISOLATION; SYSTEMIC MASTOCYTOSIS; TREATMENT RESPONSE; WELL DIFFERENTIATED SYSTEMIC MASTOCYTOSIS; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; HOSPITALIZATION; IMMUNOHISTOCHEMISTRY; NEEDLE BIOPSY; ORAL DRUG ADMINISTRATION; PATHOLOGY; RARE DISEASE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS; BIOPSY, NEEDLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASTOCYTOSIS, SYSTEMIC; PIPERAZINES; PYRIMIDINES; RARE DISEASES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84862252300     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.9973     Document Type: Article

References (35)

1. Longley BJ, Reguera MJ, Ma Y: Classes of c-KIT activating mutations: Proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 25:571-576, 2001 (Pubitemid 32506764)
2. Pardanani A, Elliott M, Reeder T, et al: Imatinib for systemic mast-cell disease. Lancet 362:535-537, 2003 (Pubitemid 36976719)
3. Akin C, Brockow K, D'Ambrosio C, et al: Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 31:686-692, 2003 (Pubitemid 36945381)
4. Droogendijk HJ, Kluin-Nelemans HJ, Van Doormaal JJ, et al: Imatinib mesylate in the treatment of systemic mastocytosis: A phase II trial. Cancer 107:345-351, 2006 (Pubitemid 44036564)
5. Pagano L, Valentini CG, Caira M, et al: Advanced mast cell disease: An Italian Hematological Multicenter experience. Int J Hematol 88:483-488, 2008
6. Vega-Ruiz A, Cortes JE, Sever M, et al: Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 33:1481-1484, 2009
7. Wasag B, Niedoszytko M, Piskorz A, et al: Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis. Exp Hematol 39:859-865, 2011
8. Nakagomi N, Hirota S: Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest 87:365-371, 2007 (Pubitemid 46474567)
9. Pardanani A, Ketterling RP, Brockman SR, et al: CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102:3093-3096, 2003 (Pubitemid 37314742)
10. Akin C, Fumo G, Yavuz AS, et al: A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103:3222-3225, 2004 (Pubitemid 38451702)
11. Zhang LY, Smith ML, Schultheis B, et al: A novel K5091 mutation of KIT identified in familial mastocytosis - in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 30:373-378, 2006 (Pubitemid 43254957)
12. Hoffmann KM, Moser A, Lohse P, et al: Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood 112:1655-1657, 2008
13. Akin C, Escribano L, Núñez R, et al: Well-differentiated systemic mastocytosis: A new disease variant with mature mast cell phenotype and lack of codon 816 c-kit mutations. J Allergy Clin Immunol 113:S327, 2004
14. Teodosio C, García-Montero AC, Jara-Acevedo M, et al: Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol 125:719-726, 2010
15. Sánchez-Munoz L, Alvarez-Twose I, García-Montero AC, et al: Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol 24:1157-1168, 2011
16. García-Montero AC, Jara-Acevedo M, Teodosio C, et al: KIT mutation in mast cells and other bone marrow haematopoietic cell lineages in systemic mast cell disorders. A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108:2366-2372, 2006 (Pubitemid 44497521)
17. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001 (Pubitemid 32267973)
18. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001 (Pubitemid 32267972)
19. Schaller JL, Burkland GA: Case report: Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 3:9, 2001
20. Ault P, Cortes J, Koller C, et al: Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 26:881-884, 2002 (Pubitemid 34790218)
21. Cortes J, Ault P, Koller C, et al: Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101:4714-4716, 2003 (Pubitemid 36857726)
22. Klion AD, Noel P, Akin C, et al: Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101:4660-4666, 2003 (Pubitemid 36857718)
23. Pardanani A, Reeder T, Porrata LF, et al: Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 101:3391-3397, 2003 (Pubitemid 36857919)
24. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056, 2001 (Pubitemid 32267975)
25. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002 (Pubitemid 34879334)
26. Ma Y, Zeng S, Metcalfe DD, et al: The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wildtype kinases and those with regulatory-type mutations. Blood 99:1741-1744, 2002
27. Mol CD, Dougan DR, Schneider TR, et al: Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279:31655-31663, 2004
28. Frost MJ, Ferrao PT, Hughes TP, et al: Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 1:1115-1124, 2002
29. Hartmann K, Wardelmann E, Ma Y, et al: Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 129:1042-1046, 2005 (Pubitemid 41242694)
30. Mital A, Piskorz A, Lewandowski K, et al: A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol 86:531-535, 2011
31. Pardanani A, Tefferi A: A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions. Eur J Haematol 84:371-378, 2010
32. Jung AG, Horny HP, Sotlar K, et al: Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis. J Am Acad Dermatol 65:224-226, 2011
33. Escribano L, Alvarez-Twose I, Sánchez-Munoz L, et al: Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 124:514-521, 2009
34. Pardanani A, Tefferi A: Systemic mastocytosis in adults: A review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol 17:125-132, 2010
35. Kiernan JA: Production and life span of cutaneous mast cells in young rats. J Anat 128:225-238, 1979